Journal
JOURNAL OF GENE MEDICINE
Volume 16, Issue 5-6, Pages 122-130Publisher
WILEY
DOI: 10.1002/jgm.2768
Keywords
adeno-associated virus; animal models; choroideremia; gene therapy; in vitro models; retina
Categories
Funding
- Choroideremia Research Foundation
- Foundation Fighting Blindness grant [TA-GT-1211-0564-UPA-WG]
- Research to Prevent Blindness
- Mackall Foundation Trust
- Penn Genome Frontiers Institute
- Pennsylvania Department of Health
- FM Kirby Foundation
- Fight for Sight [1936/38] Funding Source: researchfish
Ask authors/readers for more resources
Background Choroideremia (CHM) is a slowly progressive X-linked retinal degeneration that results in a loss of photoreceptors, retinal pigment epithelium and choroid. CHM, the gene implicated in choroideremia, encodes Rab escort protein-1 (REP-1), which is involved in the post-translational activation via prenylation of Rab proteins. Methods We evaluated AAV8.CBA.hCHM, a recombinant adeno-associated virus serotype 8 (rAAV8) vector, which targets retinal cells efficiently, for both therapeutic effect and safety in vitro and in vivo in a murine model. In vitro studies included western blot analyses and prenylation assays. In vivo studies included ophthalmoscopy, pupillometry, histology and immunofluorescence analysis. Results Infection with AAV8.CBA.hCHM induced the expression of REP-1 protein in a dose-responsive fashion. Transduction with AAV8.CBA.hCHM reverses the biochemical and pathogenetic defects in CHM both in vitro and in vivo and showed no safety concerns in the in vivo investigations performed in the present study. Conclusions AAV8 is a promising vector for human clinical gene therapy trials for choroideremia. Copyright (C) 2014 John Wiley & Sons, Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available